Moving from spreadsheets to automated data collection and processing is far from easy, but it could revolutionize drug development. It’s time for the biopharma industry to embrace end-to-end digitalization.
The next era for mRNA-based therapeutics and vaccines is here, and it’s time to move from an R&D mindset to a focus on long-term success with mRNA and bringing these innovative therapeutics to patients at scale.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Multiple studies have shown no correlation between R&D costs and the launch price of new drugs though that is an argument often used by drugmakers to prevent a cap on pricing. Still, one way to keep costs low, is for organizations to leverage health technology like AI and improve formulary compliance.
Government funding plays a major role in the advancement of drugs, including monoclonal antibodies, which are extremely expensive to produce and can take months to develop.
A drug development approach that makes use of hybrid AI can de-risk drug development while simultaneously removing other barriers to success. In other words, it has the power to significantly reduce the drug development timeline, and ultimately, save more lives.
Antisense oligonucleotides (ASOs) have faced their share of challenges, but a combination of research advances and a market ripe for innovation is setting this drug class up for a resurgence. Antisense oligonucleotide (ASO)—a class of drugs that works by targeting RNA to alter gene expression and control aberrant proteins in ways that traditional drugs can’t.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Rich Horgan believes that there's an alternative path to drug development that can lower costs and the time it takes to bring drugs to market. He is trying to apply it to the field of rare and ultra-rare diseases.
Drug developers need policies and technological infrastructure to execute on their goal of being patient-focused. At a minimum, this means a compliant way to engage patients and truly hear their voices; at its most effective, patient engagement also meets patients where they are – whenever and wherever that may be.
Abcam’s acquisition comes two months after its board announced the exploration of strategic alternatives that could include the sale of the company. Danaher beat out at least 20 companies that were potential buyers of the life sciences tools and antibody development firm.
Biopharma companies are harnessing AI tools for multiple aspects of drug development such as identifying drug development targets, modeling a drug's effect on the body, and more.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Risk-based quality management, or RBQM, is the process by which pharmaceutical organizations monitor and manage quality throughout clinical trials.
Boston Consulting Group hosted a panel during the annual J.P. Morgan Healthcare Conference in which Merck'c chief strategy officer, a healthcare leader from Goldman Sachs, an investment executive and a senior medical devices executive from Medtronic weighed in on trends the life sciences industry can expect to see in 2023.
Many pharma and medical device companies will look inward, with the goal of standardizing and modernizing even highly regulated activities. Here’s a closer look at some important industry trends for 2023.
By easing regulatory requirements for animal testing, the Act allows scientists to use innovative, leading-edge technologies more fully in future drug development strategies.
Risk-based quality management is a data monitoring approach that accelerates the drug development pathway without compromising on safety – and one that is enhanced by the use of technologies such as artificial intelligence.